Genetic testing can improve selection of women with ER positive breast cancer for ten rather than five years of hormonal therapy
Genetic testing can improve selection of women with ER positive breast cancer for ten rather than five years of hormonal therapy
EBCC 2014 key messages to doctors
Ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer
The future of mCRPC treatment - expert discussion
mCRPC management in Taiwan - expert interview
PSA as a marker of disease in patients with prostate cancer and bone metastases
Predictive power of PSA patterns during off-time treatment periods with intermittent androgen deprivation
MET variant as a prognostic marker in clear cell renal cell carcinoma
Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer
Dissecting the biology of the androgen receptor pathway
HER2 positive breast cancer treatment, past and future
Breast cancer psychosocial and survivorship issues: are we doing better?